浙江震元(000705) - 2016 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2016 was ¥2,440,003,892.51, representing a 12.69% increase compared to ¥2,163,505,548.82 in 2015[18]. - Net profit attributable to shareholders was ¥45,275,577.95, a 35.01% increase from ¥36,225,616.95 in the previous year[18]. - The net cash flow from operating activities increased by 107.82% to ¥115,993,133.87 from ¥56,744,630.69 in 2015[18]. - Basic earnings per share rose to ¥0.14, a 40.00% increase from ¥0.11 in 2015[18]. - Total assets at the end of 2016 were ¥2,017,140,314.96, reflecting a 3.49% increase from ¥1,938,191,885.92 at the end of 2015[18]. - The net assets attributable to shareholders increased by 1.99% to ¥1,293,309,710.08 from ¥1,265,350,094.02 in 2015[18]. - The company reported a total of ¥6,886,643.89 in non-recurring gains and losses for 2016, with significant contributions from government subsidies and other income[23]. - Total operating revenue for 2016 was CNY 2,439,104,892.51, an increase of 12.44% compared to the previous year[43]. - The company achieved total sales of 2.44 billion yuan, representing a year-on-year growth of 12.69%[41]. - The pharmaceutical wholesale segment generated sales of 1.65 billion yuan, up 16.28% from the previous year, while the retail segment saw sales of 422 million yuan, a 10.67% increase[42]. Cash Flow and Investments - The company reported a significant increase in cash flow from operating activities in Q4 2016, amounting to ¥116,641,159.38, compared to a negative cash flow in Q1 and Q2[22]. - Total cash and cash equivalents increased by 127.35% to CNY 44,265,579.13 compared to the previous year[51]. - Investment activities generated a net cash outflow of CNY 118,887,070.17, an improvement of 45.09% from the previous year[51]. - The company’s cash flow from operating activities showed a strong performance, indicating improved operational efficiency and cash management[176]. - Cash outflow from investment activities totaled CNY 142,997,094.57, down from CNY 223,692,901.79, indicating a reduction of 36.1%[177]. Dividends and Profit Distribution - The company plans to distribute a cash dividend of 0.20 RMB per 10 shares to all shareholders, based on a total of 334,123,286 shares[5]. - In 2016, the company achieved a net profit of CNY 53,984,713.46, with a proposed cash dividend of CNY 0.20 per share, totaling CNY 6,682,465.72[81]. - The total distributable profit for 2016 was CNY 141,721,778.40, with cash dividends accounting for 100% of the profit distribution[83]. - The cash dividend for 2015 was CNY 8,353,082.15, which represented 34.70% of the net profit of CNY 24,068,879.70[82]. Corporate Governance and Compliance - The board of directors has confirmed that all members attended the meeting to review the annual report, ensuring transparency and accountability[4]. - The company has been recognized as a national "Contract-abiding and Trustworthy" enterprise, emphasizing its commitment to social responsibility and community engagement[108]. - The company did not disclose any undisclosed significant information during the investor meetings[76]. - The company received a standard unqualified audit opinion from Tianjian Accounting Firm for the 2016 financial statements[159]. - The company maintained effective financial reporting internal controls as of December 31, 2016, according to the internal control audit report[156]. Research and Development - The company holds 20 invention patents and 2 design patents, reflecting its commitment to research and development in the pharmaceutical sector[28]. - The company has been recognized as a high-tech enterprise and has established several research centers, enhancing its technological and innovative capabilities[28]. - Research and development expenses totaled CNY 16,843,680.34, a decrease of 9.4% from the previous year, representing 0.69% of total operating revenue[49]. Market Strategy and Future Outlook - The company aims to adapt to the evolving pharmaceutical industry landscape, focusing on structural adjustments and efficiency improvements amid regulatory changes[31]. - In 2017, the company plans to focus on maintaining existing markets and expanding through enhanced logistics and supply chain services[68]. - The company plans to expand its market presence and invest in new product development to drive future growth[180]. - The company has initiated a strategy for mergers and acquisitions to enhance its competitive position in the market[181]. Shareholder Information - The total number of shares outstanding is 334,123,286, with 84.38% being unrestricted shares[112]. - The largest shareholder, Shaoxing Zhenyuan Health Industry Group Co., Ltd., holds 19.94% of the shares, totaling 66,627,786 shares[118]. - The total number of shareholders at the end of the reporting period was 31,901, a decrease from 32,196 at the end of the previous month[118]. Employee and Management Structure - Total number of employees is 1,783, with 1,624 in major subsidiaries and 159 in the parent company[137]. - The company has a total of 13 individuals receiving remuneration, indicating a structured management team[135]. - The total remuneration for 13 directors, supervisors, and senior management in 2016 amounted to 3.3642 million yuan[135]. Financial Position and Assets - The company's total liabilities increased to CNY 703,354,906.39 from CNY 666,397,737.49, reflecting a rise of about 5.2%[166]. - The total equity attributable to shareholders rose to CNY 1,293,309,710.08, up from CNY 1,268,076,086.68, indicating an increase of approximately 2.0%[166]. - The company's total current liabilities amounted to CNY 682,720,244.33, an increase from CNY 643,051,632.07, which is a rise of about 6.2%[166].